Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

CARLY Development and characterization of a novel CAR T-cell therapy for NHL

Coordinator
Fundacio Institut De Recerca Contra La Leucemia Josep Carreras, Spain
Runs
1 January 2025 to 30 June 2027
Status
Running
EU funding
€226k
Total cost
—
Partners
2 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101153028

What the project is doing

In the project's own words, from its summary on CORDIS.

Non-Hodgkin lymphomas (NHL) are a group of blood cancers characterized by the expansion of malignant B lymphocytes creating tumors throughout the body. The standard of care for patients with aggressive NHL is a combination of chemotherapy and immunotherapy. Even though it is well tolerated, ~40% of the patients respond poorly and eventually relapse. Novel personalized treatment options are now available for such individuals and engage patients’ own T cells genetically manipulated to express a chimeric antigen receptor (CAR) capable to recognize and attack malignant cells.

Thus far, CAR-T products recognizing and attacking cells expressing the protein CD19 have been approved by regulatory agencies across the planet. However, long-term follow-up studies show that more than half of these patients eventually succumb to relapse after CAR-T treatment. One of the causes for this is the loss of the CD19 protein on NHL cells. Therefore, finding other proteins beyond CD19 that could be targeted or co-targeted with CAR-T-cells is desired.

Indeed, in the proposed project, I intend to develop and characterize a CAR-T therapy directed against a cell surface protein highly expressed in NHL (preliminary data). Herein, I plan to evaluate the levels of the new target protein in a large cohort of NHL patients using immunohistochemistry and to perform a thorough preclinical assessment of this novel CAR-T-cell approach using cutting-edge preclinical NHL models. To achieve these goals, I will exploit the experience of the hosting institution in generating NHL patient-derived xenografts and in the bench-to-bedside CAR-T development process, as well as the external collaborators who are experts in blood cancer treatment.

This fellowship will significantly expose me to world-class theoretical and hands-on preclinical research in hematooncology and adoptive cell therapy, thus boosting my career as an independent researcher.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Recerca Contra La Leucemia Josep CarrerasBadalonaSpainCoordinator
Onechain Immunotherapeutics S.l.BarcelonaSpainAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI